Integral Diagnostics Ltd
ASX:IDX

Watchlist Manager
Integral Diagnostics Ltd Logo
Integral Diagnostics Ltd
ASX:IDX
Watchlist
Price: 2.91 AUD -2.02% Market Closed
Market Cap: 680.8m AUD
Have any thoughts about
Integral Diagnostics Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one IDX stock under the Base Case scenario is 10.26 AUD. Compared to the current market price of 2.91 AUD, Integral Diagnostics Ltd is Undervalued by 72%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IDX Relative Value
Base Case
10.26 AUD
Undervaluation 72%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.4
P/S
P/S
Price to Sales
1.4
vs History
77
vs Industry
62
Median 3Y
1.7
Median 5Y
2
Industry
2.3
Forward
1.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
23
Median 3Y
29.5
Median 5Y
29.7
Industry
23.2
Forward
26.7
More Details
10.3
P/OCF
P/OCF
Price to OCF
10.3
vs History
73
vs Industry
36
Median 3Y
13.2
Median 5Y
14.2
Industry
14.3
More Details
14.1
P/FCFE
P/FCFE
Price to FCFE
14.1
vs History
61
vs Industry
17
Median 3Y
21.6
Median 5Y
19.4
Industry
20.1
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
50
vs Industry
44
Median 3Y
1.9
Median 5Y
2.3
Industry
2.2
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
77
vs Industry
49
Median 3Y
2.3
Median 5Y
2.7
Industry
2.4
Forward
1.7
More Details
2.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.2
vs History
77
vs Industry
68
Median 3Y
2.4
Median 5Y
2.9
Industry
5
More Details
23.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
23.2
vs History
23
vs Industry
15
Median 3Y
23.3
Median 5Y
21.5
Industry
12.8
Forward
8.2
More Details
23.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.2
vs History
23
vs Industry
21
Median 3Y
23.3
Median 5Y
21.5
Industry
17.2
Forward
15.2
More Details
14.8
EV/OCF
EV/OCF
Enterprise Value to OCF
14.8
vs History
68
vs Industry
28
Median 3Y
16.5
Median 5Y
17.6
Industry
14
More Details
23.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
23.2
vs History
76
vs Industry
10
Median 3Y
54.4
Median 5Y
43.4
Industry
18.2
More Details
1.5
EV/IC
EV/IC
Enterprise Value to IC
1.5
vs History
50
vs Industry
51
Median 3Y
1.4
Median 5Y
1.5
Industry
1.9
More Details

Multiples Across Competitors

IDX Competitors Multiples
Integral Diagnostics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Integral Diagnostics Ltd
ASX:IDX
680.7m AUD 1.4 -11.2 23.2 23.2
US
Cigna Group
XMUN:CGN
75B EUR 0.3 25.7 8 10.4
US
Cigna Corp
NYSE:CI
77.2B USD 0.3 25.4 8 10.3
US
CVS Health Corp
NYSE:CVS
56.5B USD 0.2 11.3 9.6 9.6
DE
Fresenius Medical Care AG
XMUN:FME
25.9B EUR 1.3 39.2 10.7 23.1
DE
Fresenius SE & Co KGaA
XETRA:FRE
18.9B EUR 0.9 -49.3 9.3 19
US
Laboratory Corporation of America Holdings
NYSE:LH
19.2B USD 1.5 44.1 13.2 20.3
US
R1 RCM Inc
NASDAQ:RCM
17.7B USD 7.2 -289.7 38.3 99.1
US
Quest Diagnostics Inc
NYSE:DGX
16.9B USD 1.8 20.2 12.2 16.5
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13B EUR 0.7 19.7 6.6 14.3
US
DaVita Inc
NYSE:DVA
12.4B USD 1 14.9 7.8 10.9
P/E Multiple
Earnings Growth PEG
AU
Integral Diagnostics Ltd
ASX:IDX
Average P/E: 25.1
Negative Multiple: -11.2 		N/A N/A
US
C
Cigna Group
XMUN:CGN
25.7
25%
1
US
Cigna Corp
NYSE:CI
25.4
25%
1
US
CVS Health Corp
NYSE:CVS
11.3
3%
3.8
DE
Fresenius Medical Care AG
XMUN:FME
39.2
31%
1.3
DE
Fresenius SE & Co KGaA
XETRA:FRE
Negative Multiple: -49.3 N/A N/A
US
Laboratory Corporation of America Holdings
NYSE:LH
44.1
54%
0.8
US
R1 RCM Inc
NASDAQ:RCM
Negative Multiple: -289.7
253%
N/A
US
Quest Diagnostics Inc
NYSE:DGX
20.2
12%
1.7
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
19.7
31%
0.6
US
DaVita Inc
NYSE:DVA
14.9
17%
0.9

See Also

Summary
IDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IDX stock valuation using valuation multiples.
Wall Street Estimates
IDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 212,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.